“People with POTS often also have autoimmune diseases, and similar immune-related connections are emerging in long COVID, with evidence suggesting the immune system may disrupt nerves that regulate functions like heart rate and digestion, though experts don't classify either POTS or long COVID as autoimmune disorders themselves”

**The National Geographic article is real and the caption accurately represents it.** The article exists at nationalgeographic.com and frames the topic exactly as the post describes: researchers are studying the connection between autoimmune diseases and conditions like POTS and long COVID in hopes it might lead to more targeted treatments, and experts believe autoimmune diseases can cause autonomic nervous system dysfunction by fraying and inflaming the nerves that tell the heart and other organs what to do . **On autoimmune comorbidity in POTS.** The underlying numbers are real and consistent across multiple independent datasets. A clinical review states that 16% to 20% of patients with POTS have a coexisting autoimmune disease, and many have a family history of one, with the most common coexisting conditions in a large community-based survey being Hashimoto thyroiditis (6%), celiac disease (3%), Sjögren syndrome (3%), rheumatoid arthritis (2%), and lupus (2%) . The primary chart-review study found that in a cohort that was 90% female with mean age 32, 25% had positive antinuclear antibodies, 7% had at least one antiphospholipid antibody, and 31% had markers of autoimmunity; compared with the general population, POTS patients had higher prevalence of ANA (25% vs 16%), aPL antibody (7% vs 1%) and comorbid autoimmune disorders (20% vs highest estimated 9.4%, OR 2.4) . A separate large registry effort confirms this independently: a 3,300-patient POTS registry and survey developed by Dysautonomia International, Vanderbilt University and the University of Calgary found that 16% of POTS patients have been diagnosed with an autoimmune disease . **On the mechanism (immune system disrupting autonomic nerves).** There is genuine experimental evidence. A JAHA study reported that among 14 POTS patients and 10 healthy subjects, the sera of all 14 POTS patients demonstrated significant arteriolar contractile activity (69±3% vs 91±1% of baseline for healthy controls, P<0.001), suppressed by alpha-1 adrenergic blockade with prazosin . A rabbit model found that adrenergic autoantibodies induced a POTS-like phenotype including exacerbated orthostatic tachycardia and adrenergic receptor dysfunction that was suppressed by selectively clearing the antibodies . **On the "experts don't classify it as autoimmune" qualifier.** This is the most defensible part of the claim and matches the expert consensus. The NIH consensus statement is explicit: in most of these autoantibody studies, similarly reactive antibodies have been found in healthy control groups, although less frequently or at lower levels than in POTS patients, and despite preliminary animal-model support, a causal role of these autoantibodies in POTS is not established . **Important counterevidence the caption omits.** A validation study directly undercut the most-cited autoantibody findings: autoantibody concentrations against all 11 receptors tested were not significantly different between controls and POTS patients; 98.3% of POTS patients and 100% of controls had alpha-1 adrenergic receptor autoantibody concentrations above the manufacturer's seropositive threshold, receiver operating characteristic curves showed poor ability to discriminate, and the authors concluded these tests are not useful for establishing the role of autoimmunity in POTS . **On long COVID.** The systematic review evidence is real but heterogeneous. A 2025 *Lancet Infectious Diseases* systematic review found that 31 of 44 studies (71%) reported an association between autoantibodies and long COVID, but there was substantial heterogeneity in study design, type and timing of antibody measurements, and long COVID definitions . Variability in study designs and definitions limits conclusions, and larger studies are needed to confirm any diagnostic or prognostic role . Another systematic review noted that while the majority of evidence suggests a potential association between autoantibodies and post-COVID conditions, the clinical significance appears to be small, and conflicting results were observed across studies . At least one recent study reported that no correlation was observed between autoantibody presence and disease severity, and the findings do not support a primary pathogenic role for the evaluated autoantibodies in long COVID . A review specifically on this overlap concludes: multiple autoantibodies are identified in both COVID-related autonomic disorders and non-COVID autonomic disorders, implying a possible underlying autoimmune pathology, but the lack of specificity of these findings precludes direct interpretations of cause and association .